Publications

Start here

Eleven papers that define the program.

1. 2026

   uPAR/suPAR Signaling and Organ Crosstalk in Cardiovascular-Kidney-Metabolic Syndrome

   Circulation Research First author

   Comprehensive mechanistic review reframing uPAR/suPAR as compartmentalized signaling system in CKM syndrome: membrane uPAR drives local inflammation/remodeling, soluble suPAR mediates remote organ injury via αvβ3-integrin/RAGE activation

2. 2024

   Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association

   Circulation First author

   AHA scientific statement providing comprehensive guidance on cardiovascular evaluation, risk stratification, and management across all phases of hematopoietic stem cell transplantation from pretransplant assessment through long-term survivorship

3. 2023

   Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

   JACC. CardioOncology Senior author

   The 100-day and 5-year cumulative incidence of CV events after HSCT were 4.1% and 13.9%; allogeneic recipients had higher incidence of long-term CV events compared to autologous recipients (16.4% vs 12.1%).

4. 2023

   The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease

   Science Translational Medicine Co-author

   D2D3 uPAR fragment impairs pancreatic beta-cell function and causes glomerular injury in transgenic mice; anti-uPAR antibody restores beta-cell mass and function.

5. 2023

   Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

   Nature medicine Co-author

   Thymic epithelial tumors were associated with 18-fold higher ICI-myocarditis risk, earlier onset, higher mortality (64% vs 23% at 30 days), and more severe myotoxicities compared to other cancers.

6. 2022

   Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis

   JACC. CardioOncology Senior author

   ICI myocarditis incidence was 1.0%; CPK elevation was sensitive (99%) for myocarditis and predicted all-cause mortality independent of cardiac biomarkers.

7. 2022

   Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis

   Journal of Clinical Investigation Senior author

   suPAR levels predict coronary calcification and CVD events; GWAS identified PLAUR rs4760 variant causing elevated suPAR; Mendelian randomization shows causality; suPAR-transgenic mice develop larger atherosclerotic plaques via proinflammatory monocyte priming

8. 2020

   Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI

   Journal of the American Society of Nephrology Senior author

   Admission suPAR levels predicted AKI and dialysis need in 352 COVID-19 patients; highest tertile had 9.15-fold increased AKI odds and 22.86-fold dialysis odds, independent of inflammatory markers.

9. 2020

   Soluble Urokinase Receptor and Acute Kidney Injury

   The New England journal of medicine First author

   Highest suPAR quartile associated with 2.66-fold higher odds of AKI; suPAR overexpression in mice worsened contrast-induced AKI; anti-uPAR antibody attenuated kidney injury, establishing suPAR as biomarker and therapeutic target

10. 2017

    A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease

    Nature medicine First author

    APOL1 G1/G2 risk variants conferred CKD risk only when suPAR elevated; mechanistically, APOL1 variants bind suPAR-activated αvβ3 integrin with higher affinity, causing podocyte injury.

11. 2015

    Soluble Urokinase Receptor and Chronic Kidney Disease

    The New England journal of medicine First author

    Higher suPAR predicted 3.1-fold increased incident CKD risk and greater eGFR decline, with annual decline of -4.2 ml/min/1.73m² in highest quartile versus -0.9 in lowest.